Imugene Ltd managing director and CEO Leslie Chong talked with Proactive about the first complete response reported in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort of the company’s ongoing Phase 1b azer-cel trial. Chong said the result was an important milestone for patients with limited remaining treatment options, particularly those who had relapsed on or become refractory to BTKi therapy. The first patient in the cohort, who had follicular lymphoma and had previously failed BTKi therapy, achieved a complete response at the Day 28 assessment. Chong explained that a complete response means the patient’s cancer was “completely gone”, adding that patients who fail BTK inhibitors often have few alternatives. She said Imugene is evaluating whether azer-cel can be used concurrently with BTKi therapy to help restore or enhance treatment activity. She also highlighted the commercial relevance of BTKi therapy, describing it as a market worth about US$12 billion. Chong said azer-cel’s off-the-shelf, allogeneic CAR-T profile could offer an availability advantage compared with traditional autologous CAR-T therapies, which may require patients to wait several weeks for their own cells to be re-engineered. Imugene has dosed four patients so far in the concurrent BTKi combination cohort and plans to provide further updates as the dataset matures. Visit Proactive's YouTube channel for more videos, and don't forget to give this video a like, subscribe to the channel and enable notifications for future content. #Imugene #IMU #IUGNF #AzerCel #BTKi #BrutonTyrosineKinase #CAR_T #CellTherapy #CancerResearch #BCellMalignancies #FollicularLymphoma #Lymphoma #Biotech #ASXStocks #HealthcareStocks #ClinicalTrials #Phase1b #Oncology #InvestorNews #ProactiveInvestors